An observational study in Sarcoma, Osteosarcoma and Ewing Sarcoma, sponsored by University of Milano Bicocca. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.
Sponsored by University of Milano Bicocca · Observational
Application of computational statistics and machine learning methods to data derived from electronic health records of patients diagnosed with sarcoma.
This observational, retrospective, multicenter study will be conducted on a group of patients treated at the Rizzoli Orthopedic Institute in Bologna and followed throughout their treatment. The study population includes patients of both sexes and all ages, affected by the two types of bone sarcoma typical of young people, with histologically confirmed diagnoses. The musculoskeletal tumors referred to in the study are osteosarcoma (OS) and Ewing's sarcoma (ES). Both are rare and very aggressive tumors, with a prognosis that remains unsatisfactory. These characteristics limit the possibility of conducting ad hoc studies on large case series that would allow the characterization of patients affected by these conditions in order to identify prognostic predictors. The clinical registries of specialized centers such as the Rizzoli Orthopedic Institute (IOR), which has always been a reference point for the diagnosis and treatment of sarcomas, are a source of very relevant data in this regard, allowing the collection of observational data gathered prospectively over time. The aim of this retrospective observational study is to characterize clusters of patients with different prognostic profiles and, secondarily, to identify the most predictive characteristics with respect to the prognosis of patients, applying computational intelligence algorithms using the open-source programming language R to already available data.
At the Simple Departmental Structure (SSD) of Anatomy and Pathological Histology of the Rizzoli Orthopaedic Institute (IOR), two datasets containing these variables are available and ready for use:
Following ethical approval, access to these data will be requested, to be subsequently analyzed with computational intelligence algorithms (e.g., Random Forests) to determine the characteristics most predictive of prognosis (using a technique called "recursive feature elimination").
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's enrollment of 700 is above the median of 121 across 238 observational studies indexed under Sarcoma.
Browse Sarcoma studies →University of Milano Bicocca is the lead sponsor of 124 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Information unavailable.
Inclusion criteria: confirmed diagnosis of osteosarcoma or Ewing sarcoma between 2003 and 2012 at the IRCCS Rizzoli Orthopaedic Institute.
Exclusion criteria: diagnosis other than osteosarcoma or Ewing sarcoma and/or diagnosis made before 2003 and after 2012.
Data of patients diagnosed with osteosarcoma
Other: No intervention studied
Data of patients diagnosed with Ewing sarcoma
Other: No intervention studied
No intervention studied
Survival
Survival of patients during the follow-up
Time frame: 6 months
No study locations are listed for this record.
Plan to share: Undecided — If we have the authorization from the Ethical Committee of the IOR hospital, we might consider sharing the data in the future.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Milano Bicocca